---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-115943"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2021-09-15T23:59:59+00:00"
generated_at: "2026-06-29T03:28:17.362967+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash

## Summary
- Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.
- Milestone payments include up to 750,000 Series A preferred shares and up to $11M in cash tied to clinical development.
- Royalty of 15% on net sales of licensed products; TheraCour retains manufacturing rights.
- President Anil Diwan's employment extended to June 30, 2022 with $400K base salary and 10,204 Series A shares vesting quarterly.

## SEC filing metadata
- accession: 0001104659-21-115943
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2021-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/0001104659-21-115943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465921115943/tm2127721d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-115943
- JSON: https://secwatch.observer/filing/0001104659-21-115943.json
- Plain text: https://secwatch.observer/filing/0001104659-21-115943.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.